Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a frequent complication in patients with cancer [1]. It is estimated that 20–30 % of VTE cases are secondary to neoplasm [1]. These patients face a 3 to 9-fold higher risk of developing VTE compared to the general population [1]. Clinical practice guidelines advise that individuals with cancer associated thrombosis (CAT) should undergo at least 3 to 6 months of anticoagulant therapy [2–4]. Extended anticoagulation should be considered for specific patients with active cancer, such as those with metastatic disease or those undergoing oncological treatments [5,6].
